期刊文献+

度洛西汀治疗抑郁发作伴躯体症状患者62例的临床疗效 被引量:1

Clinical efficacy and effect of duloxetine in the treatment of 62 patients with depressive episode accompanied by somatic symptoms
下载PDF
导出
摘要 目的:分析研究度洛西汀治疗抑郁发作伴躯体症状的临床效果以及对患者产生的影响。方法:收治抑郁发作伴躯体症状患者62例,将患者随机分为两组。其中观察组患者采用度洛西汀进行治疗,对照组患者采用氟西汀进行治疗,观察对比两组患者的治疗效果以及治疗过程中的不良反应。结果:经治疗,两组患者的抑郁及躯体症状出现明显改善,其中观察组患者在连续治疗1个疗程后,症状改善比率约90%,对照组患者症状改善比率约74%,明显低于观察组。结论:度洛西汀治疗抑郁发作伴躯体症状具有相对较好的治疗效果,并且对于患者的不良影响相对较小。 Objective:To study the clinical effect of duloxetine in the treatment of depressive episode with somatic symptoms and its influence on patients.Methods:62 depressive patients with somatic symptoms were selected,they were randomly divided into the two groups.The observation group was treated with duloxetine and the control group was treated with fluoxetine.We observed and compared the therapeutic effect and adverse reactions in the course of treatment between the two groups.Results:After treatment,the depression and somatic symptoms of the two groups were significantly improved.After one course of treatment,the improvement rate of symptoms in the observation group was about 90%,and that in the control group was about 74%,which was significantly lower than that in the observation group.Conclusion:Duloxetine is effective in the treatment of depressive episodes with somatic symptoms,and has relatively little adverse effects on patients.
作者 林海谛 季长亮 付荣 Lin Haidi;Ji Changliang;Fu Rong(Yunnan Psychiatric Hospital,Yunnan Kunming 650000)
出处 《中国社区医师》 2019年第8期53-54,共2页 Chinese Community Doctors
关键词 度洛西汀 抑郁 躯体症状 临床效果 不良影响 Duloxetine Depression Somatic symptoms Clinical effects Adverse effects
  • 相关文献

参考文献2

二级参考文献34

  • 1温新民,毛庆华,汤建,虞心红.度洛西汀的合成进展[J].合成化学,2004,12(6):551-554. 被引量:11
  • 2ANATHEA B W, PETER K. Duloxetine hydrochloride [ J ]. Nat Rev, 2004,3 ( 11 ) :907 - 908.
  • 3FDA [ EB/OL]. http://www, fda. gov/cder/foi/label/2004/2173- 31b1/pdf,2004 09 29/2005 03 16.
  • 4GALABRESE F, MOLTENI R, MAJ P F ,et al. Chronic duloxetine dreatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein[ J ]. Neuro Psycho Pharmacology , 2007,32 ( 11 ) : 2351 - 2359.
  • 5MIRZA N R,NIELSEN E O,TROELSEN K B. Serotonin transporter density and anxiolytic-like effects of antidepressants in mice [ J ]. Prog Neuropsychopharmacol Biol Psychiatry, 2007,31 ( 4 ) : 858 - 866.
  • 6WESTANMO A D, GAYKEN J, HAIGHT R. Duloxetine:a balanced and selective norepinephrine-and serotonin-reuptake inhibitor[ J ]. Am J Health Syst Pharm, 2005,62 ( 23 ) : 2481 - 2490.
  • 7ISHIGOOKA J, NAGATA E, TAKAHASHI A, et al. Simultaneous monitoring of inhibition of serotonin uptake by platelets and plasma drug concentrations following administration of duloxetine, a new antidepressant candidate, to healthy volunteers [ J ]. Curr Ther Res, 1997,58(10) :679 -692.
  • 8LOTT R S, BAKER D E. Duloxetine : a new antidepressant [ J ]. Adv Pharmacy ,2003 ,1 (3) :228 -241.
  • 9BYMASTER F P, DRESHFELD-AHMAD L J,THRELKELD P G,et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors [ J 1. Neuropsychopharmacology, 2001, 25 (6) : 871-880.
  • 10CACCIAS A. Metabolism of the newest antidepressants:comparisons with related predecessors [ J ]. Ther Drugs,2004,7 ( 2 ) : 143 - 150.

共引文献25

同被引文献19

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部